Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-06
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 2
- Registration Number
- NCT00033306
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Georgia Cancer Specialists, Atlanta, Georgia, United States
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00026273
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇦🇹Allgemeines Krankenhaus der Stadt Wien, Vienna (Wien), Austria
🇩🇪Universitats-Krankenhaus Eppendorf, Hamburg, Germany
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 86
- Registration Number
- NCT00064181
- Locations
- 🇪🇬
National Cancer Institute - Cairo, Cairo, Egypt
🇭🇺National Institute of Oncology, Budapest, Hungary
🇩🇪Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 94
- Registration Number
- NCT00063960
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University Medical Group, Providence, Rhode Island, United States
🇺🇸University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00026364
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1302
- Registration Number
- NCT00063141
- Locations
- 🇬🇧
ImClone Investigational Site, Sutton, Surrey, United Kingdom
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00024141
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Irinotecan on a Weekly Schedule in Children
- First Posted Date
- 2003-06-18
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 23
- Registration Number
- NCT00062842
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
- Conditions
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- American College of Radiology Imaging Network
- Registration Number
- NCT00023868
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 58
- Registration Number
- NCT00027612
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.